215 related articles for article (PubMed ID: 10824041)
21. Activity of gemifloxacin, a new broad-spectrum quinolone, against 200 pneumococci by four different susceptibility testing methods.
Ednie LM; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2000 Apr; 45(4):525-8. PubMed ID: 10747832
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
[TBL] [Abstract][Full Text] [Related]
23. Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis.
Cottagnoud P; Acosta F; Cottagnoud M; Täuber MG
Antimicrob Agents Chemother; 2002 May; 46(5):1607-9. PubMed ID: 11959614
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of gemifloxacin compared with other antimicrobial agents against recent clinical isolates of streptococci.
Ieven M; Goossens W; De Wit S; Goossens H
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():51-3. PubMed ID: 10824033
[TBL] [Abstract][Full Text] [Related]
25. Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.
Jones RN; Deshpande LM; Erwin ME; Barrett MS; Beach ML
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():67-70. PubMed ID: 10824035
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.
Lemmen S; Al-Lahham A; Lütticken R; Reinert RR
Chemotherapy; 2001; 47(2):104-9. PubMed ID: 11173811
[TBL] [Abstract][Full Text] [Related]
27. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
[TBL] [Abstract][Full Text] [Related]
28. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
Heaton VJ; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
[TBL] [Abstract][Full Text] [Related]
29. Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro.
Higgins PG; Coleman K; Amyes SG
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():71-7. PubMed ID: 10824036
[TBL] [Abstract][Full Text] [Related]
30. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770
[TBL] [Abstract][Full Text] [Related]
31. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
George J; Morrissey I
J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
[TBL] [Abstract][Full Text] [Related]
32. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
Visalli MA; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1996 Jan; 37(1):77-84. PubMed ID: 8647777
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics to combat resistance.
Woodnutt G
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():25-31. PubMed ID: 10997596
[TBL] [Abstract][Full Text] [Related]
34. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
[TBL] [Abstract][Full Text] [Related]
35. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
Weiss K; Laverdiere M; Restieri C
J Antimicrob Chemother; 1998 Oct; 42(4):523-5. PubMed ID: 9818753
[TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
Dubois J; St-Pierre C
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():41-6. PubMed ID: 10824031
[TBL] [Abstract][Full Text] [Related]
37. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
38. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
Lopez H; Stepanik D; Vilches V; Scarano S; Sarachian B; Mikaelian G; Finlay J; Sucari A
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
[TBL] [Abstract][Full Text] [Related]
39. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
Marchese A; Debbia EA; Schito GC
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
[TBL] [Abstract][Full Text] [Related]
40. A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.
Hoban DJ; Bouchillon SK; Karlowsky JA; Johnson JL; Butler DL; Miller LA; Poupard JA
Antimicrob Agents Chemother; 2000 Nov; 44(11):3008-11. PubMed ID: 11036014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
